European Heart Rhythm Association (EHRA) 2021 Annual Congress

Population screening for AF may reduce negative outcomes

Roshini Claire Anthony, 20210604180001

Widespread screening for atrial fibrillation (AF) may reduce clinical outcomes, suggested findings of the STROKESTOP trial.

Arrhythmia may be a harbinger of death in cannabis users

Elvira Manzano, 20210528105000

Arrhythmia may increase the risk of death among cannabis users admitted to the hospital, as shown in a study presented at EHRA 2021.

Targeted therapy effect on sinus rhythm in early AF may not stand the test of time

Roshini Claire Anthony, 20210527180001

The benefit of targeted therapy on sinus rhythm at 1 year in patients with early persistent atrial fibrillation (AF) and heart failure (HF) was not sustained at 5 years, according to results of the RACE 3* trial presented at EHRA 2021.

His-bundle pacing gains foothold in heart failure with LBBB

Pearl Toh, 20210523140100

Cardiac resynchronization therapy (CRT) with His-bundle pacing led to successful and lasting cardiac resynchronization in almost three-quarters of patients with symptomatic heart failure (HF) and left bundle branch block (LBBB), shows the His-Alternative study presented at EHRA 2021.

No added benefits from weight loss post-ablation for AF patients

Pearl Toh, 20210513140100

Undergoing a structured weight loss programme after ablation for atrial fibrillation (AF) does not confer significant reduction in AF burden compared with usual care, according to the SORT-AF* study presented at EHRA 2021.